Navigation Links
Press conference schedule announced for TCT 2009
Date:8/27/2009

WHAT:

Data from late-breaking clinical trials of new interventional techniques and devices will be released at TCT 2009 - Transcatheter Cardiovascular Therapeutics the global annual scientific symposium of the Cardiovascular Research Foundation. Researchers will present a variety of new data that promises to advance the field of interventional cardiology.

The TCT 2009 final program is now available at: http://www.tctconference.com/pdf/tct2009-final-program.pdf. The program is also now searchable online by presentations and speakers at: http://www.tctconference.com/program/program-search.html.

WHEN: The TCT Scientific Symposium will be held September 21-25, 2009.

Late-breaking clinical trials will be highlighted during press conferences scheduled for Wednesday, September 23, Thursday, September 24, and Friday, September 25.

Wednesday, September 23, 2009
9:30am - 10:30am

  • SPIRIT IV: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
  • FAME: Two-Year Follow-up from a Prospective Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
  • ISAR-DESIRE 2: A Prospective Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Sirolimus-Eluting Stent Restenosis
  • SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-up from a Prospective Randomized Trial of Paclitaxel-Eluting and Sirolimus-Eluting Stents
  • LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
  • COMPARE: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Thursday, September 24, 2009
9:00am - 10:00am

  • TRITON-TIMI 38 ECONOMIC SUBSTUDY: Cost-Effectiveness of Prasugrel vs. Clopidogrel from a Prospective Randomized Trial of Patients with ACS Undergoing PCI
  • CURRENT-PCI OASIS 7: A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
  • PROSPECT: A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
  • COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel
  • CHARISMA GENOMICS SUBSTUDY: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
  • PLATO INVASIVE: A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy

Friday, September 25, 2009
9:30am - 10:30am

  • SYMPLICITY 1: One-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
  • DEBATER: A Prospective Randomized Trial of Drug-Eluting vs. Bare-Metal Stents With or Without Abciximab in STEMI
  • BCIS-1: A Prospective Randomized Trial of Intra-Aortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
  • FAUST: A Prospective Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
  • NORDIC-BALTIC BIFURCATION STUDY III: A Prospective Randomized Trial of Side Branch Dilatation Strategies in Patients with Coronary Bifurcation Lesions Undergoing Treatment with a Single Stent
  • HORIZONS-AMI: Two-Year Follow-up from a Prospective Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI

WHERE:
The Moscone Center
San Francisco, CA


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. Clinical depression linked to abnormal emotional brain circuits
4. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
5. Specific antagonism lowers blood pressure
6. Are too many people diagnosed as depressed?
7. Depression Taking Toll on Returning U.S. Vets
8. Doctors Often Miss High Blood Pressure in Kids
9. Pill box organizers increase HIV patients adherence and improve viral suppression
10. Damp, Moldy Homes May Cause Depression
11. Treating depression may improve recovery of heart rate variability following coronary syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. ... Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at ... Maisel, founder of Retina Group of New York , is a Board ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... comprehensive treatment for eating disorders, is opening a brand new child and adolescent ... ages 8-17 and their families with even more specialized eating disorder treatment and ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... ... On May 23rd during the National Eye Institute’s “Healthy Vision Month”, Sharon ... honored by Ashram, Inc. as the world’s foremost water visionary. , “Sharon Kleyne is ... the Nile to fill their red clay pots with life-sustaining water.” Said Ashram co-founder ...
(Date:5/26/2016)... ... 2016 , ... Saint Francis Hospital & Medical Center has ... have paid off. Since implementation of these efforts, surgical errors and readmissions ... patient experiences and reduce costly complications. Since implementation in 2011, safety efforts have: ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... 2016 Digital Health Dialog, LLC dba ... the US Patent and Trademark Office of U.S. ... processes for electronic opt-­in and processing of discount ... HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to opt­-in ...
Breaking Medicine Technology: